Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
Study sponsor: Gain Therapeutics, Inc. · GANX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-06-30Estimated
Enrollment · participants111Estimated
Source updated2025-12-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.